LIM Domain Only-2 (LMO2) induces T-cell leukemia by two distinct pathways

Stephen Smith, Rati Tripathi, Charnise Goodings, Susan Cleveland, Elizabeth Mathias, J. Andrew Hardaway, Natalina Elliott, Yajun Yi, Xi Chen, James Downing, Charles Mullighan, Deborah A. Swing, Lino Tessarollo, Qi Li, Paul Love, Nancy A. Jenkins, Neal G. Copeland, Mary Ann Thompson, Yang Du, Utpal P. Davé

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The LMO2 oncogene is deregulated in the majority of human T-cell leukemia cases and in most gene therapy-induced T-cell leukemias. We made transgenic mice with enforced expression of Lmo2 in T-cells by the CD2 promoter/enhancer. These transgenic mice developed highly penetrant T-ALL by two distinct patterns of gene expression: one in which there was concordant activation of Lyl1, Hhex, and Mycn or alternatively, with Notch1 target gene activation. Most strikingly, this gene expression clustering was conserved in human Early T-cell Precursor ALL (ETP-ALL), where LMO2, HHEX, LYL1, and MYCN were most highly expressed. We discovered that HHEX is a direct transcriptional target of LMO2 consistent with its concordant gene expression. Furthermore, conditional inactivation of Hhex in CD2-Lmo2 transgenic mice markedly attenuated T-ALL development, demonstrating that Hhex is a crucial mediator of Lmo2's oncogenic function. The CD2-Lmo2 transgenic mice offer mechanistic insight into concordant oncogene expression and provide a model for the highly treatment-resistant ETP-ALL subtype.

Original languageEnglish (US)
Article numbere85883
JournalPLoS One
Volume9
Issue number1
DOIs
StatePublished - Jan 21 2014
Externally publishedYes

Fingerprint

T-Cell Leukemia
T-cells
leukemia
Transgenic Mice
T-lymphocytes
T-Lymphoid Precursor Cells
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Gene expression
genetically modified organisms
Oncogenes
Gene Expression
oncogenes
mice
gene expression
Chemical activation
Gene therapy
gene activation
Genetic Therapy
gene therapy
Transcriptional Activation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Smith, S., Tripathi, R., Goodings, C., Cleveland, S., Mathias, E., Hardaway, J. A., ... Davé, U. P. (2014). LIM Domain Only-2 (LMO2) induces T-cell leukemia by two distinct pathways. PLoS One, 9(1), [e85883]. https://doi.org/10.1371/journal.pone.0085883

LIM Domain Only-2 (LMO2) induces T-cell leukemia by two distinct pathways. / Smith, Stephen; Tripathi, Rati; Goodings, Charnise; Cleveland, Susan; Mathias, Elizabeth; Hardaway, J. Andrew; Elliott, Natalina; Yi, Yajun; Chen, Xi; Downing, James; Mullighan, Charles; Swing, Deborah A.; Tessarollo, Lino; Li, Qi; Love, Paul; Jenkins, Nancy A.; Copeland, Neal G.; Thompson, Mary Ann; Du, Yang; Davé, Utpal P.

In: PLoS One, Vol. 9, No. 1, e85883, 21.01.2014.

Research output: Contribution to journalArticle

Smith, S, Tripathi, R, Goodings, C, Cleveland, S, Mathias, E, Hardaway, JA, Elliott, N, Yi, Y, Chen, X, Downing, J, Mullighan, C, Swing, DA, Tessarollo, L, Li, Q, Love, P, Jenkins, NA, Copeland, NG, Thompson, MA, Du, Y & Davé, UP 2014, 'LIM Domain Only-2 (LMO2) induces T-cell leukemia by two distinct pathways', PLoS One, vol. 9, no. 1, e85883. https://doi.org/10.1371/journal.pone.0085883
Smith S, Tripathi R, Goodings C, Cleveland S, Mathias E, Hardaway JA et al. LIM Domain Only-2 (LMO2) induces T-cell leukemia by two distinct pathways. PLoS One. 2014 Jan 21;9(1). e85883. https://doi.org/10.1371/journal.pone.0085883
Smith, Stephen ; Tripathi, Rati ; Goodings, Charnise ; Cleveland, Susan ; Mathias, Elizabeth ; Hardaway, J. Andrew ; Elliott, Natalina ; Yi, Yajun ; Chen, Xi ; Downing, James ; Mullighan, Charles ; Swing, Deborah A. ; Tessarollo, Lino ; Li, Qi ; Love, Paul ; Jenkins, Nancy A. ; Copeland, Neal G. ; Thompson, Mary Ann ; Du, Yang ; Davé, Utpal P. / LIM Domain Only-2 (LMO2) induces T-cell leukemia by two distinct pathways. In: PLoS One. 2014 ; Vol. 9, No. 1.
@article{17f0c43a9dc3430490be8d67daaef638,
title = "LIM Domain Only-2 (LMO2) induces T-cell leukemia by two distinct pathways",
abstract = "The LMO2 oncogene is deregulated in the majority of human T-cell leukemia cases and in most gene therapy-induced T-cell leukemias. We made transgenic mice with enforced expression of Lmo2 in T-cells by the CD2 promoter/enhancer. These transgenic mice developed highly penetrant T-ALL by two distinct patterns of gene expression: one in which there was concordant activation of Lyl1, Hhex, and Mycn or alternatively, with Notch1 target gene activation. Most strikingly, this gene expression clustering was conserved in human Early T-cell Precursor ALL (ETP-ALL), where LMO2, HHEX, LYL1, and MYCN were most highly expressed. We discovered that HHEX is a direct transcriptional target of LMO2 consistent with its concordant gene expression. Furthermore, conditional inactivation of Hhex in CD2-Lmo2 transgenic mice markedly attenuated T-ALL development, demonstrating that Hhex is a crucial mediator of Lmo2's oncogenic function. The CD2-Lmo2 transgenic mice offer mechanistic insight into concordant oncogene expression and provide a model for the highly treatment-resistant ETP-ALL subtype.",
author = "Stephen Smith and Rati Tripathi and Charnise Goodings and Susan Cleveland and Elizabeth Mathias and Hardaway, {J. Andrew} and Natalina Elliott and Yajun Yi and Xi Chen and James Downing and Charles Mullighan and Swing, {Deborah A.} and Lino Tessarollo and Qi Li and Paul Love and Jenkins, {Nancy A.} and Copeland, {Neal G.} and Thompson, {Mary Ann} and Yang Du and Dav{\'e}, {Utpal P.}",
year = "2014",
month = "1",
day = "21",
doi = "10.1371/journal.pone.0085883",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - LIM Domain Only-2 (LMO2) induces T-cell leukemia by two distinct pathways

AU - Smith, Stephen

AU - Tripathi, Rati

AU - Goodings, Charnise

AU - Cleveland, Susan

AU - Mathias, Elizabeth

AU - Hardaway, J. Andrew

AU - Elliott, Natalina

AU - Yi, Yajun

AU - Chen, Xi

AU - Downing, James

AU - Mullighan, Charles

AU - Swing, Deborah A.

AU - Tessarollo, Lino

AU - Li, Qi

AU - Love, Paul

AU - Jenkins, Nancy A.

AU - Copeland, Neal G.

AU - Thompson, Mary Ann

AU - Du, Yang

AU - Davé, Utpal P.

PY - 2014/1/21

Y1 - 2014/1/21

N2 - The LMO2 oncogene is deregulated in the majority of human T-cell leukemia cases and in most gene therapy-induced T-cell leukemias. We made transgenic mice with enforced expression of Lmo2 in T-cells by the CD2 promoter/enhancer. These transgenic mice developed highly penetrant T-ALL by two distinct patterns of gene expression: one in which there was concordant activation of Lyl1, Hhex, and Mycn or alternatively, with Notch1 target gene activation. Most strikingly, this gene expression clustering was conserved in human Early T-cell Precursor ALL (ETP-ALL), where LMO2, HHEX, LYL1, and MYCN were most highly expressed. We discovered that HHEX is a direct transcriptional target of LMO2 consistent with its concordant gene expression. Furthermore, conditional inactivation of Hhex in CD2-Lmo2 transgenic mice markedly attenuated T-ALL development, demonstrating that Hhex is a crucial mediator of Lmo2's oncogenic function. The CD2-Lmo2 transgenic mice offer mechanistic insight into concordant oncogene expression and provide a model for the highly treatment-resistant ETP-ALL subtype.

AB - The LMO2 oncogene is deregulated in the majority of human T-cell leukemia cases and in most gene therapy-induced T-cell leukemias. We made transgenic mice with enforced expression of Lmo2 in T-cells by the CD2 promoter/enhancer. These transgenic mice developed highly penetrant T-ALL by two distinct patterns of gene expression: one in which there was concordant activation of Lyl1, Hhex, and Mycn or alternatively, with Notch1 target gene activation. Most strikingly, this gene expression clustering was conserved in human Early T-cell Precursor ALL (ETP-ALL), where LMO2, HHEX, LYL1, and MYCN were most highly expressed. We discovered that HHEX is a direct transcriptional target of LMO2 consistent with its concordant gene expression. Furthermore, conditional inactivation of Hhex in CD2-Lmo2 transgenic mice markedly attenuated T-ALL development, demonstrating that Hhex is a crucial mediator of Lmo2's oncogenic function. The CD2-Lmo2 transgenic mice offer mechanistic insight into concordant oncogene expression and provide a model for the highly treatment-resistant ETP-ALL subtype.

UR - http://www.scopus.com/inward/record.url?scp=84902293435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902293435&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0085883

DO - 10.1371/journal.pone.0085883

M3 - Article

C2 - 24465765

AN - SCOPUS:84902293435

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e85883

ER -